Compare Ascendis Pharma A/S (ASND) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Fortinet Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Fortinet Inc trades at $158.75 (market cap $115.40B). The key difference: Fortinet Inc is far larger — about 6.5× Ascendis Pharma A/S's market cap. Which is the better fit depends on your goals.
| ASND | FTNT | |
|---|---|---|
Market Cap | $17.74B | $115.40B |
Sector | Health | Technology |
52-Week High | $277.18 | $163.73 |
52-Week Low | $163.32 | $74.39 |
Enterprise Value | $18.11B | $112.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Fortinet (FTNT) trades at $157.51, down 3.8% over the past day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.82 versus $0.619 expected, and maintains robust profitability with a net income margin of 27.49%. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the stock up significantly year-to-date.
The outlook remains positive due to sustained earnings beats and sector tailwinds, but high valuation multiples (P/E of 61.05) and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $117.42 suggests caution relative to the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
